Echo IQ (ASX:EIQ) Partners with Mayo Clinic Platform, Advances EchoSolv HF towards FDA Clearance
Echo IQ (ASX:EIQ) partners with Mayo Clinic Platform to advance EchoSolv HF and progress towards FDA clearance for its heart failure solution.
Tag: Investor Relations
Race Oncology (ASX:RAC) Activates First Australian Clinical Site for RC220 Trial
Race Oncology (ASX:RAC) initiates its first Australian clinical site for the Phase 1 RC220 trial, marking a significant step in advancing cancer treatment.
Bioxyne Limited (ASX:BXN) Signs Exclusive $7M Agreement with NectarTek
Bioxyne Limited (ASX:BXN) secures a $7 million manufacturing agreement with NectarTek, significantly increasing FY2026 revenue projections.
Biome Australia Limited (ASX:BIO) Secures $5.0M Debt Facility with NAB
Biome Australia Limited (ASX:BIO) secures a $5.0 million debt facility with NAB to drive growth and enhance financial stability.
Epsilon Healthcare Limited (ASX:EPN) Enters Voluntary Administration
Epsilon Healthcare Limited (ASX:EPN) enters voluntary administration, resulting in leadership changes and subdued operations.
Bigtincan Holdings Limited (ASX:BTH) Announces Proposed Acquisition and Option Scheme
Bigtincan Holdings Limited (ASX:BTH) announces a proposed acquisition by Big Wombat and outlines share and option schemes for shareholder approval.
Fisher & Paykel Healthcare (ASX:FPH) Addresses Impact of New US Tariffs
Fisher & Paykel Healthcare (ASX:FPH) outlines its response to new US tariffs, detailing operational and financial strategies.
Cochlear Limited (ASX:COH) Awaits Clarification on US Tariff
Cochlear Limited (ASX:COH) awaits clarification on new US export tariffs, expecting further details and market updates soon.
Pure Hydrogen Corporation Limited (ASX:PH2) Secures Landmark Agreement with GreenH2 LATAM
Pure Hydrogen Corporation Limited (ASX:PH2) secures a $44 million agreement with GreenH2 LATAM to supply hydrogen infrastructure for Mexican projects.
Atomos Limited (ASX:AMS) Enters $13.7m Debt Facility
Atomos Limited (ASX:AMS) secures a $13.7m debt facility to achieve cashflow positivity by FY26, avoiding equity dilution.